A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence

Trial Profile

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 24 May 2016 Interim analysis results (n=74) presented at the Digestive Disease Week 2016.
    • 17 Apr 2016 Interim results (n=74) presented at The International Liver Congress™ 2016.
    • 19 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top